Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients

Jetske M. Meerum Terwogt(Amsterdam Public Health), Jos H. Beijnen(Slotervaartziekenhuis), Olaf van Tellingen(Dutch Cancer Society), Manon Huizing(The Netherlands Cancer Institute), Marcel US Boschma(Slotervaartziekenhuis), W.W. ten Bokkel Huinink, Jan HM Schellens(Slotervaartziekenhuis), Vinodh R. Nannan Panday(Slotervaartziekenhuis), C.H.N. Veenhof(Amsterdam UMC Location University of Amsterdam), Giuseppe Giaccone(Cornell University)
Anti-Cancer Drugs
October 1, 2000
10.1097/00001813-200010000-00003
Cited by 11

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2009|913